Folia Cardiologica 2024, 19 DOI: 10.5603/fc.98758 Copyright © 2024 Via Medica ISSN 2353-7752 e-ISSN 2353-7760

Minimally invasive treatment of cardiac device-related infective endocarditis using AngioVac system followed by transvenous lead extraction

Małoinwazyjne leczenie odelektrodowego zapalenia wsierdzia z użyciem systemu Angiovac i przezskórnym usunięciem elektrod

Przemysław Lipski¹, Jerzy Sacha^{1, 2}, Grzegorz Hordyński¹, Tomasz Pawlik¹, Jarosław Bugajski¹, Wojciech Milejski¹, Robert Kiwus³, Paweł Tomaszewski⁴, Marek Gierlotka¹

¹Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Opole, Poland
²Faculty of Physical Education and Physiotherapy, Opole University of Technology, Opole, Poland
³Department of Anaesthesiology, University Hospital, Institute of Medical Sciences, University of Opole, Opole, Poland
⁴Department of Cardiac Surgery, University Hospital, Faculty of Natural Sciences and Technology, University of Opole, Opole, Poland

Case report

Infection is one of the most serious complications of cardiac implantable electronic device therapy and is associated with significant mortality and morbidity [1]. This study presents a case of a patient with cardiac device-related infective endocarditis (CDRIE).

A 67-year-old patient with a past medical history of ischaemic heart failure, and peripheral artery disease, after implantation of cardiac resynchronization therapy defibrillator (CRT-D) and percutaneous coronary interventions was admitted with increased dyspnoea and unexplained fever. The lab test revealed elevated inflammatory markers. Three sets of blood cultures were positive for Streptococcus gallolitycus. Transoesophageal echocardiography (TEE) confirmed the presence of many vegetations (the largest 3,8 cm x 1.7 cm) on the lead in the right atrium (Figure 1A, 1B).

Using the modified Duke Criteria scoring system (positive blood culture and TEE evidence confirming endocardial involvement) infective endocarditis was diagnosed.

A specific antibiotic therapy was initiated. The treatment options were discussed by the local Heart Team. Due to high surgical risk, the decision was to remove vegetation mass percutaneously using the AngioVac system (AngioDynamics, Latham, NY, USA) and then lead extraction during one procedure [2]. After informed consent was obtained, the procedure was conducted under general anaesthesia in a hybrid operating room with on-site cardiac surgery support. Under fluoroscopy and ultrasound guidance, a 26 French Dry Seal sheath (Gore Medical) was placed in the right internal jugular vein (suctioning cannula) and a 23 French cannula of the venovenous bypass system was placed into the right femoral vein (re-infusion cannula). Then the suctioning cannula was carefully advanced into the close proximity of the mass (Figure 1C).

The venovenous bypass circuit was started with the centrifugal pump (RotaFlow ECMO system, Maquet Cardiovascular) generating a flow of up to 5 litres per minute and multiple aspirations were done with the successful clearing out of vegetation material (Figure 1E).

Address for correspondence: Przemysław Lipski, Department of Cardiology, University Hospital, Institute of Medical Sciences, University of Opole, Katowicka 68, 45-060 Opole, Poland, e-mail: przelipski@wp.pl

Received: 01.01.2024 Accepted: 02.04.2024 Early publication date: 07.06.2024

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.




Figure 1. A. 2D transoesophageal echocardiography (TEE) revealed large, mobile mass attached to the cardiac resynchronization therapy-defibrillator lead in the right atrium (RA) B. 3D TEE of the mass in the RA C. The AngioVac suctioning cannula is inserted into the RA under TEE and fluoroscopy guidance D. Transvenous lead extraction is being performed using Evolution RL Lead Extraction tools (Cook Vascular Inc.) E. Extracted vegetation in the AngioVAC filter F. 30-day follow-up period: 2D TEE showing connective tissue remnants and no signs of endocarditis

A subsequent total lead extraction was performed using Evolution RL Lead Extraction tools (Cook Vascular Inc.) (Figure 1D). Both vascular access sites were successfully closed with Proglides. Postprocedural TEE demonstrated the absence of the mass and no mechanical complication. The patient tolerated the procedure well and was transferred to the intensive care unit for close observation. After surgery, antibiotic treatment was continued for six weeks. Repeated blood cultures were negative. During 30-day and 6-month follow-up no clinical or ultrasound findings of endocarditis were noticed (Figure 1F).

Conclusion

The AngioVac system with subsequent mechanical lead extraction is a minimally invasive and effective procedure in the management of CDRIE patients with large vegetation.

Additional information

Ethics statement

The case report was in adherence with the Declaration of Helsinki. The written informed consent was obtained from the patient for publication of this case report and accompanying images.

Author contributions

All authors contributed to patient diagnosis, management and clinical data analysis. PL wrote the manuscript draft. All authors revised the manuscript.

Conflict of interests

The authors declare no conflict of interest

Funding

None.

Refferences

- Blomström-Lundqvist C, Traykov V, Erba PA, et al. ESC Scientific Document Group. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID) and the Europe-
- an Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Europace. 2020; 22(4): 515–549, doi: 10.1093/europace/euz246, indexed in Pubmed: 31702000.
- Sacha J, Lipski P, Bugajski J, et al. Percutaneous treatment of right heart endocarditis. Kardiol Pol. 2023; 81(10): 1028–1029, doi: 10.33963/KP.a2023.0176, indexed in Pubmed: 37537923.